Search

everythinglearnresearchcommunity

for

Search:↓

Testosterone replacement may help some postmenopausal women with symptoms like fatigue and low libido, but more research is needed to fully understand its effects.

Long-term estrogen therapy in postmenopausal women can improve certain health markers, hair loss is common regardless of hormone use, stopping estrogen doesn't increase breast cancer risk, smoking does, and a balanced BMI is linked to lower mortality.

Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

The combination therapy is effective and well-tolerated for treating esophageal cancer.

The combination treatment reduced prostate size and improved testosterone deficiency symptoms but was less effective for sexual function.

ADT-G may be a useful indicator of increased androgen levels in women with acne and can be lowered with certain birth control pills.

Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Antiandrogens help treat hormone-related conditions in both men and women.

Dutasteride may help shrink prostate cancer tumors.

New drug dutasteride effectively treats hair loss, but use cautiously due to potential sexual side effects.

Androgen therapy can help with symptoms like low libido in women, but more research is needed to understand its long-term safety and effects on health.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

Antiandrogen therapy may be beneficial for women with hidradenitis suppurativa.

Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.

The drug combination was safe and showed promise in treating advanced tumors.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.

Both LNG-IUD and systemic progestins are effective for fertility-sparing treatment, but close monitoring is needed due to recurrence risk.

Androgen deprivation therapy might be better for preventing COVID-19 than treating it.

Anthracycline and taxane chemotherapy cause significant side effects like fatigue, vomiting, nausea, nerve damage, joint pain, and hair loss in breast cancer patients.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

Combining low-dose dutasteride with finasteride improved a man's hair loss.

Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.

Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.

Localized estrogen treatments may improve skin quality with fewer risks than systemic hormone therapy.

New hormonal therapies can help treat advanced prostate cancer but may cause testicular issues.

Retinoids may improve hair growth in androgenic alopecia when used with other treatments.